Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Vanda Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Vanda PharmaceuticalsDie Umsatzerlöse des Unternehmens werden voraussichtlich um 2.7% pro Jahr zurückgehen, während die jährlichen Gewinne voraussichtlich um 30.9% pro Jahr wachsen werden. Der Gewinn pro Aktie wird voraussichtlich um 28.8% pro Jahr wachsen.

Wichtige Informationen

30.9%

Wachstumsrate der Gewinne

28.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.7%
Wachstumsrate der Einnahmen	-2.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	27 Apr 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much

Apr 05

Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Feb 15

Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash

Feb 13

Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement

Feb 10

News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts

Nov 11

One Forecaster Is Now More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be

May 12

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:VNDA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	152	9	298	299	1
12/31/2025	232	-19	254	255	1
12/31/2024	195	-4	190	191	1
3/31/2024	178	-5	-115	-11	N/A
12/31/2023	193	3	-88	13	N/A
9/30/2023	212	12	26	26	N/A
6/30/2023	238	15	40	41	N/A
3/31/2023	257	16	59	60	N/A
12/31/2022	254	6	31	32	N/A
9/30/2022	258	6	49	49	N/A
6/30/2022	263	11	45	46	N/A
3/31/2022	266	18	59	59	N/A
12/31/2021	269	33	64	64	N/A
9/30/2021	268	34	56	57	N/A
6/30/2021	259	32	55	57	N/A
3/31/2021	253	32	60	62	N/A
12/31/2020	248	23	50	52	N/A
9/30/2020	241	19	41	42	N/A
6/30/2020	241	114	38	39	N/A
3/31/2020	237	117	34	35	N/A
12/31/2019	227	116	45	46	N/A
9/30/2019	219	122	50	51	N/A
6/30/2019	209	28	53	54	N/A
3/31/2019	197	22	12	38	N/A
12/31/2018	193	25	5	30	N/A
9/30/2018	184	13	-7	18	N/A
6/30/2018	177	1	-14	12	N/A
3/31/2018	171	-5	4	5	N/A
12/31/2017	165	-16	N/A	-2	N/A
9/30/2017	159	-14	N/A	-7	N/A
6/30/2017	156	-10	N/A	-8	N/A
3/31/2017	150	-13	N/A	-9	N/A
12/31/2016	146	-18	N/A	-8	N/A
9/30/2016	140	-32	N/A	-7	N/A
6/30/2016	129	-41	N/A	-13	N/A
3/31/2016	121	-42	N/A	2	N/A
12/31/2015	110	-40	N/A	12	N/A
9/30/2015	93	45	N/A	-1	N/A
6/30/2015	80	53	N/A	-3	N/A
3/31/2015	63	36	N/A	-52	N/A
12/31/2014	50	20	N/A	-82	N/A
9/30/2014	44	-57	N/A	-80	N/A
6/30/2014	37	-61	N/A	-83	N/A
3/31/2014	35	-43	N/A	-54	N/A
12/31/2013	34	-21	N/A	-40	N/A
9/30/2013	33	-20	N/A	-41	N/A
6/30/2013	33	-20	N/A	-41	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: VNDA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: VNDA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: VNDA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: VNDADie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-2.7% pro Jahr).

Hohe Wachstumseinnahmen: VNDADie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-2.7% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von VNDA in 3 Jahren voraussichtlich hoch sein wird

Vanda Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 23% to US$5.21

Consensus EPS estimates fall from profit to US$0.06 loss, revenue upgraded

Consensus revenue estimates increase by 27%

Price target increased to US$11.00

Vanda Pharmaceuticals Inc. Revises Financial Guidance for the Year 2022

Consensus EPS estimates increase by 11%

Recent updates

Cycle Pharmaceuticals Limited made a proposal to acquire Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) for approximately $490 million.

Future Pak, Ltd. cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., Renaissance Technologies LLC, BlackRock, Inc. (NYSE:BLK), Butler Hall Capital LLC, Shareholder Capital LLC and others.

Vanda Pharmaceuticals Inc. Reports Positive Results from A Second Phase III Study of Tradipitant in Motion Sickness

First quarter 2024 earnings released: US$0.072 loss per share (vs US$0.057 profit in 1Q 2023)

Price target increased by 23% to US$5.21

Vanda Pharmaceuticals Inc. to Report Q1, 2024 Results on May 08, 2024

Future Pak, Ltd. submits a proposal to acquire Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., State Street Corporation (NYSE:STT), BlackRock, Inc. (NYSE:BLK), Dimensional Fund Advisors LP and others for approximately $450 million.

Future Pak, Ltd. submits a proposal to acquire Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., State Street Corporation (NYSE:STT), BlackRock, Inc. (NYSE:BLK), Dimensional Fund Advisors LP and others for approximately $450 million.

Consensus EPS estimates fall from profit to US$0.06 loss, revenue upgraded

Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much

New minor risk - Share price stability

Vanda Pharmaceuticals' Fanapt (Iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder

Insider recently sold US$73k worth of stock

Founder notifies of intention to sell stock

Vanda Pharmaceuticals Announces FDA Update for Supplemental NDA for HETLIOZ in the Treatment of Insomnia

Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Consensus revenue estimates increase by 27%

Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash

Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia

Vanda Pharmaceuticals Inc. to Report Q4, 2023 Results on Feb 07, 2024

Vanda Pharmaceuticals Inc. Announces U.S. Food and Drug Administration Approval for VTR-297 for the Treatment of Onychomycosis

Vanda Pharmaceuticals Inc. Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S

Now 21% undervalued after recent price drop

Vanda Pharmaceuticals Inc. Announces U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis

Now 21% undervalued after recent price drop

News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts

Third quarter 2023 earnings released: EPS: US$0.002 (vs US$0.058 in 3Q 2022)

Vanda Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 08, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Vanda Pharmaceuticals Inc. to Report Q2, 2023 Results on Jul 27, 2023

Senior VP recently sold US$96k worth of stock

Senior VP notifies of intention to sell stock

Vanda Pharmaceuticals Inc Reports Results from a Phase III study of Tradipitant in Motion Sickness

One Forecaster Is Now More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be

Vanda Pharmaceuticals Inc. Responds to the Ruling in its Hetlioz(R) Abbreviated New Drug Application Appeal

First quarter 2023 earnings released: EPS: US$0.057 (vs US$0.12 loss in 1Q 2022)

Insider recently sold US$105k worth of stock

Founder notifies of intention to sell stock

Insufficient new directors

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Vanda Pharmaceuticals Inc. to Report Q4, 2022 Results on Feb 08, 2023

Vanda Pharmaceuticals Inc. Announces Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study

Senior VP recently sold US$56k worth of stock

Vanda Pharmaceuticals Provides an Update to HETLIOZ ANDA Litigation Appeal: Federal Circuit Grants Motion to Temporarily Enjoin Generic Launch

Now 45% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Founder notifies of intention to sell stock

Vvanda Pharmaceuticals Inc. Reports Results in A Phase II Clinical Study of Vqw-765 in the Treatment of Acute Performance Anxiety

Price target increased to US$11.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Vanda Pharmaceuticals Inc. Revises Financial Guidance for the Year 2022

Vanda Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 02, 2022

Now 20% undervalued after recent price drop

Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Vanda Pharmaceuticals Inc. Securities Litigation

Vanda Pharmaceuticals: What The Recent Partnership Entails

Vanda Pharma, OliPass collaborate to develop oligonucleotide-based therapeutics

Vanda Pharmaceuticals Inc. Announces Notice of Opportunity for an FDA Hearing on the sNDA for HETLIOZ in Jet Lag Disorder

Consensus EPS estimates increase by 11%

Senior VP recently sold US$86k worth of stock

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Vanda Pharmaceuticals Inc. Provides Revenue Guidance for the Full Year 2022

Vanda Pharmaceuticals Q2 Earnings Preview

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie